NYSE$SDEV

NovaBay Pharmaceuticals Inc · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

Saddle Ranch Media reported Q1 2025 net income attributable to common stockholders of $7.7M with diluted EPS of $1.42.

Net income attributable to common stockholders was $7.7 million, or $1.42 per diluted share, primarily from discontinued operations while continuing operations posted a loss. General and administrative costs and legacy warrant accounting affect comparability.

  • Q1 net income to common $7.7M; EPS $1.42.
  • Discontinued operations drove quarterly profitability.
  • Continuing operations net loss from operations ~$3.3M.
  • Legacy liabilities and warrant fair value remain watch items.

Headline financials

Total Revenue

$0.00

Previous: $2.63M-100.0%
EPS (adj)

$1.42

Previous: -$4.90+129.0%
Net Loss from Continuing Operations

-$3.33M

No prior period
Net Income from Discontinued Operations

$11M

No prior period
Basic EPS from Continuing Operations

-$0.63

No prior period
Basic EPS from Discontinued Operations

$2.07

No prior period
Diluted EPS from Continuing Operations

-$0.61

No prior period
Diluted EPS from Discontinued Operations

$2.03

No prior period
Impairment of Long-Lived Assets

$589K

No prior period
Operating Lease Expense

$71K

No prior period
Weighted-Average Remaining Lease Term (years)

2.3

No prior period
Weighted-Average Discount Rate

0.1%

No prior period
Total Current Assets, Discontinued Operations (Avenova)

$1.18M

No prior period
Total Current Liabilities, Discontinued Operations (Avenova)

$1.15M

No prior period
Gain on Divestiture (Avenova)

$10.7M

No prior period
Net Sales, Discontinued Operations (Wound Care)

$122K

No prior period
Gain on Divestiture (Wound Care)

$500K

No prior period
Avenova net sales

$433K

No prior period
General and administrative expenses

$2.7M

No prior period
Net Income

$7.67M

Previous: -$3.21M+338.6%
Operating Income

-$3.29M

Previous: -$2.44M-35.1%

Revenue & EPS history

NovaBay · Revenue · Quarterly

$0

Q1 2025-100%vs Q1 2024
Beat estimate in 3 of 14 quarters(21%)
ActualEstimate

Forward guidance

The filing discusses strategic priorities, liquidity, and sector risks without numeric forward EPS guidance.

Tailwinds

  • Management outlines growth initiatives and capital allocation.
  • Segment commentary supports the investment narrative.

Headwinds

  • Macro and input-cost pressure on margins.
  • One-time items may affect comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

-0.9%

Avg return

Earnings day

-3.9%

Avg return

5 days after

-6.5%

Avg return

30 days after

37%

24 / 65 earnings

Positive

+74.0%

Q2 2016

Best reaction

-51.1%

Q1 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.0%
Q4 2026+8.7%+8.7%-6.5%
Q3 2025+0.0%+3.8%+46.2%
Q2 2025+3.3%+71.7%+331.7%
Q1 2025-1.8%-3.5%+7.0%
Q3 2024-2.9%+8.3%-19.4%
Q2 2024+11.6%+0.9%-81.6%
Q1 2024-9.9%-11.1%-14.0%
Q4 2023-13.7%-23.1%-38.5%
Q3 2023-2.9%+0.0%-12.1%
Q2 2023-1.5%-11.6%-10.1%
Q1 2023-0.8%-26.5%-30.6%
Q4 2022+3.0%+3.0%-30.3%
Q3 2022-3.4%-34.0%-44.4%
Q2 2022-10.0%-16.1%-41.9%
Q1 2022+4.9%+11.1%+22.2%
Q4 2021-3.0%-6.3%-25.0%
Q3 2021-7.6%-7.1%-1.8%
Q2 2021+0.4%-7.9%+0.0%
Q1 2021-5.6%-5.3%-5.3%
Q4 2020-9.2%-12.9%-20.8%
Q3 2020-1.3%-6.5%+11.3%
Q2 2020-16.2%-24.3%-42.6%
Q1 2020-8.9%-11.6%-25.0%
Q4 2019-13.3%-31.8%+2.3%
Q3 2019-11.6%-15.9%-15.9%
Q2 2019-2.5%-26.3%-55.9%
Q1 2019-51.1%-15.1%-62.8%
Q4 2018-4.2%-22.4%-20.8%
Q3 2018+7.2%+6.4%+13.6%
Q2 2018-10.2%-9.9%-40.3%
Q1 2018+4.3%+1.4%-4.4%
Q4 2017+2.9%+5.7%-4.3%
Q3 2017+4.4%+9.5%-18.6%
Q2 2017+2.4%+8.2%+3.5%
Q1 2017-6.7%-12.3%-14.1%
Q4 2016-0.9%+1.6%-13.0%
Q3 2016-12.6%-10.4%-13.6%
Q2 2016+74.0%+63.9%+27.7%
Q1 2016+5.7%
Q4 2015+7.1%
Q3 2015-7.3%
Q2 2015-4.0%
Q1 2015+11.2%
Q4 2014-5.6%
Q3 2014-0.0%
Q2 2014+5.1%
Q1 2014-4.4%
Q4 2013+0.0%
Q3 2013+1.0%
Q2 2013+2.1%
Q1 2013+6.3%
Q4 2012+2.4%
Q3 2012-2.3%
Q2 2012-2.5%
Q1 2012-0.8%
Q4 2011-4.2%
Q4 2009-4.2%
Q3 2011-9.1%
Q4 2010+11.4%
Q2 2011+11.4%
Q1 2011+1.5%
Q3 2010-0.2%
Q2 2010-0.5%
Q1 2010+4.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro